Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:PTGX NASDAQ:TGTX NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$33.62+2.3%$29.08$14.32▼$36.28$6.75B0.762.52 million shs1.14 million shsPTGXProtagonist Therapeutics$109.780.0%$101.71$49.38▼$111.78$7.06B1.85551,559 shs448,850 shsTGTXTG Therapeutics$49.52+3.1%$38.38$25.28▼$50.41$7.36B1.681.82 million shs2.55 million shsTYRATyra Biosciences$26.99+5.6%$33.68$8.98▼$40.65$1.52B0.75870,875 shs1.01 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+5.45%+0.64%+14.76%+34.70%+103.59%PTGXProtagonist Therapeutics+3.80%+6.81%+9.84%+18.87%+98.39%TGTXTG Therapeutics+3.07%+18.47%+12.95%+71.85%+25.39%TYRATyra Biosciences+0.59%-5.92%-26.67%-29.40%+151.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$33.62+2.3%$29.08$14.32▼$36.28$6.75B0.762.52 million shs1.14 million shsPTGXProtagonist Therapeutics$109.780.0%$101.71$49.38▼$111.78$7.06B1.85551,559 shs448,850 shsTGTXTG Therapeutics$49.52+3.1%$38.38$25.28▼$50.41$7.36B1.681.82 million shs2.55 million shsTYRATyra Biosciences$26.99+5.6%$33.68$8.98▼$40.65$1.52B0.75870,875 shs1.01 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+5.45%+0.64%+14.76%+34.70%+103.59%PTGXProtagonist Therapeutics+3.80%+6.81%+9.84%+18.87%+98.39%TGTXTG Therapeutics+3.07%+18.47%+12.95%+71.85%+25.39%TYRATyra Biosciences+0.59%-5.92%-26.67%-29.40%+151.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3311.05% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.214.95% UpsideTGTXTG Therapeutics 2.71Moderate Buy$52.506.02% UpsideTYRATyra Biosciences 2.86Moderate Buy$46.0070.43% UpsideCurrent Analyst Ratings BreakdownLatest TYRA, IMVT, PTGX, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026TYRATyra Biosciences Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$37.00 ➝ $42.006/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/27/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.005/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/19/2026TYRATyra Biosciences Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/APTGXProtagonist Therapeutics$46.02M153.41N/AN/A$9.83 per share11.17TGTXTG Therapeutics$616.29M12.30$2.89 per share17.15$4.08 per share12.14TYRATyra BiosciencesN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8617.3118.01N/A65.95%88.73%43.44%8/3/2026 (Estimated)TYRATyra Biosciences-$119.95M-$2.18N/AN/AN/AN/A-42.66%-39.79%8/13/2026 (Estimated)Latest TYRA, IMVT, PTGX, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/13/2026Q1 2026TYRATyra Biosciences-$0.60-$0.64-$0.04-$0.64N/AN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09PTGXProtagonist TherapeuticsN/A17.7617.76TGTXTG Therapeutics1.285.815.12TYRATyra BiosciencesN/A20.4920.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%PTGXProtagonist Therapeutics98.63%TGTXTG Therapeutics58.58%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%PTGXProtagonist Therapeutics5.19%TGTXTG Therapeutics10.64%TYRATyra Biosciences12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableTYRATyra Biosciences2059.47 million52.04 millionOptionableTYRA, IMVT, PTGX, and TGTX HeadlinesRecent News About These CompaniesIs Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?June 12 at 9:27 AM | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | insidermonkey.comTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAYMay 21, 2026 | prnewswire.comWolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendationMay 20, 2026 | msn.comTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMay 17, 2026 | fool.comAssessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price MomentumMay 15, 2026 | finance.yahoo.comHot Picks: Cancer biotech stocks gain ground amid M&A activityMay 13, 2026 | bnnbloomberg.caBTyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings ResultsMay 13, 2026 | marketbeat.comTyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTyra Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsMay 13, 2026 | prnewswire.comTyra Biosciences to Participate in Upcoming Investor ConferencesMay 7, 2026 | prnewswire.comTyra Biosciences faces earnings test ahead of key trial dataApril 29, 2026 | investing.comTyra Bioscience, IncApril 25, 2026 | edition.cnn.comTyra Bioscience (TYRA) Receives a Buy from OppenheimerApril 25, 2026 | theglobeandmail.comGuggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibApril 24, 2026 | insidermonkey.comTyra Biosciences, Inc. ($TYRA) CEO 2025 Pay RevealedApril 17, 2026 | quiverquant.comQTyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsApril 17, 2026 | prnewswire.comGuggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 16, 2026 | msn.comCanaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 7, 2026 | msn.comA Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial ProgressApril 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYRA, IMVT, PTGX, and TGTX Company DescriptionsImmunovant NASDAQ:IMVT$33.62 +0.74 (+2.25%) Closing price 04:00 PM EasternExtended Trading$33.67 +0.05 (+0.16%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Protagonist Therapeutics NASDAQ:PTGX$109.78 -0.01 (-0.01%) Closing price 04:00 PM EasternExtended Trading$109.80 +0.02 (+0.02%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.TG Therapeutics NASDAQ:TGTX$49.52 +1.47 (+3.06%) Closing price 04:00 PM EasternExtended Trading$49.28 -0.24 (-0.47%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Tyra Biosciences NASDAQ:TYRA$26.99 +1.42 (+5.55%) Closing price 04:00 PM EasternExtended Trading$27.04 +0.05 (+0.19%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
